Prognostic value of primary tumor volume after concurrent chemoradiation with daily low‐dose cisplatin for advanced‐stage head and neck carcinoma

Abstract

In advanced-stage head and neck squamous cell carcinoma treated with concurrent chemoradiation, primary tumor volume is associated with locoregional control and survival. Larger studies are needed to confirm whether incorporation of tumor volume in the staging system improves prediction of treatment outcome and can serve as a tool to guide treatment options.

Effectiveness of CT assists for intraarterial chemotherapy: therapeutic outcome of chemoradiation for advanced head and neck cancer extending across the anatomical midline

“…A larger tumor volume is thought to be a major factor in determining a poor therapeutic outcome [13]. In the present study, there were no differences in the OS and LRC rates between the two groups.…”

Primary Tumor Site as a Predictor of Treatment Outcome for Definitive Radiotherapy of Advanced-Stage Oral Cavity Cancers

“…Tumor burden is a known predictor of the response to definitive RT (28,29). The T stage represents the primary tumor burden; however, it is not a statistically significant prognostic factor for the PFS.…”

Feasibility Study of Moderately Accelerated Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin After Induction Chemotherapy in Locally Advanced Head-and Neck Cancer

“…Induction (neoadjuvant) chemotherapy (IC) could have the potential to reduce the incidence of distant metastases. Furthermore, IC, by downsizing the tumor, could improve local control probability of subsequent definitive concurrent radiochemotherapy (5). However, for locally advanced and unresectable HNC, IC has been evaluated in clinical trials for more than two decades without any consistent proof of benefit.…”